Just received email from meeting organization chairman.Who did...

Just received email from meeting organization chairman.
Who did research in terms of Cynata Therapeutics? Please contribute some details.

Please have a look.

Dear Registrants

We apologize again for not being able to complete the on-line webinar last Thursday 10 September Stem Cells for Treatment of COVID19.

The 3 speakers on the Program, who were experts in the field, were:

1. Dr Silviu Itescu, CEO of Mesoblast. He is a physician scientist who expanded from an academic background to establish the company Mesoblast, which is both on the ASX and the NASDAQ, the American stock exchange. Earlier this year Dr Itescu reported some very promising results with the company’s product, Remestemcel-l, in a small number of COVID-19 affected patients in ICU with acute respiratory distress syndrome (ARD). This has led to a placebo controlled trial underway with the product in the USA, with several Australian hospitals now approved to be involved in this trial.

2. Associate Professor Rebecca Lim, Scientific Director of Monash Health & Translation Precinct. Professor Lim is an NHMRC Career Development Fellow, who has championed the use of amniotic epithelial cells, obtained from placentae, for a variety of medical disorders. These include cerebral palsy, premature babies with respiratory dysplasia, cirrhosis, perianal fistula associated with Crohn’s disease, and acute ischaemic stroke. Exosome based therapeutics is one of the strategies Professor Lim is using, and has expanded into the commercial arena with this strategy. She and her colleagues have a trial called ACCOLADE for treatment of ARD caused by COVID19.

3. Dr Kilian Kelly, COO of Cynata Therapeutics. This company is championing mesenchymal stem cells obtained from induced pluripotent stem cells, with approval for their use in Japan to treat graft versus host disease. Dr Kelly is well known in the field of regenerative medicine. He started his career in academia in the pharmaceutical sciences, and has since branched out to the commercial world. He is currently using his skills to both promote and advance Cymerus, the name of the anti-inflammatory cells produced by Cynata Therapeutics, including their use in the MEND Trial for treatment of ARD caused by COVID-19.

Each of the speakers has kindly made available a slide deck for registrants to peruse (attached), just as they would have, if the planned webinar had gone to completion.

Happy viewing.

Bernie Tuch
Chairman

NSW Stem Cell Network